Receive real-time job alerts and never miss the right job again
US - MA - Boston
January 7, 2025
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. • argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker...
US - MA - Boston
January 5, 2025
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. • argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker...
US - US
January 11, 2025
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. • argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor...
US - MA - Boston
January 9, 2025
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. • argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker...
US - US
January 7, 2025
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. • argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor...
US - MA - Boston
January 9, 2025
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. • argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor...
US - US
December 31, 2024
Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. • argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor...